NEI Research News

LambdaVision, the Farmington, Connecticut-based biotech firm that developed the artificial retina, is exploring optimizing production of an artificial retina in space, in a series of missions to the International Space Station.

Scientists at the University of Pennsylvania School of Veterinary Medicine report findings of a gene therapy to treat a severe form of Leber congenital amaurosis, caused by mutations in the NPHP5 gene.

Early treatment with anti-VEGF injections slowed diabetic retinopathy in a clinical study from the DRCR Retina Network (DRCR.net). However, two years into the four-year study its effect on vision was similar to standard treatment.

NEI-funded research at Scripps Research Institute has turned up more than a dozen gene variants linked to MacTel, a rare eye disease. The variants are likely causing the condition to develop and worsen for a significant share of patients.

The latest research from the John A. Moran Eye Center reveals how an oxidized form of cholesterol can change choroidal endothelial cells into cells that become scars and may wreak havoc in the eyes of age-related macular degeneration (AMD) patients.

Scientists at the University of Utah have invented a method for synthesizing large enough quantities of very-long-chain polyunsaturated fatty acids (VLC-PUFAs) to evaluate their potential sight-preserving properties.

Scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy for a rare disease that causes severe vision loss in childhood.

In experiments in mouse tissues and human cells, Johns Hopkins Medicine researchers say they have found that removing a membrane that lines the back of the eye may improve the success rate for regrowing nerve cells damaged by blinding diseases.

A team of scientists have created a molecular catalog that describes the different types of retinal ganglion cells in zebrafish, linking them to specific connections, functions, and behaviors.

Surgical and injectable drug approaches are equally effective for treatment of bleeding inside the eye from proliferative diabetic retinopathy (PDR), according to a National Eye Institute (NEI)-supported clinical study from the DRCR Retina Network .